Atrovent Hfa is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is protected by 5 US drug patents filed from 2013 to 2015. Out of these, 1 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 17, 2030. Details of Atrovent Hfa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8474447 | Inhaler device |
Jan, 2030
(4 years from now) | Active |
| US6739333 | Stainless steel canister for propellant-driven metering aerosols |
May, 2020
(4 years ago) |
Expired
|
| US6983743 | Stainless steel canister for propellant-driven metering aerosols |
May, 2020
(4 years ago) |
Expired
|
| US5683677 | Medicinal aerosol formulations |
Nov, 2014
(10 years ago) |
Expired
|
| US5676930 | Stabilized medicinal aerosol solution formulations |
Oct, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Atrovent Hfa's patents.
Latest Legal Activities on Atrovent Hfa's Patents
Given below is the list of recent legal activities going on the following patents of Atrovent Hfa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Sep, 2020 | US8474447 |
| Electronic Review Critical | 01 Oct, 2014 | US8474447 |
| Email Notification Critical | 01 Oct, 2014 | US8474447 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Allowance | 29 Sep, 2014 | US8474447 |
| Mail O.P. Petition Decision | 29 Sep, 2014 | US8474447 |
| O.P. Petition Decision | 29 Sep, 2014 | US8474447 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Allowance | 29 Sep, 2014 | US8474447 |
| Petition Entered | 25 Jun, 2014 | US8474447 |
| Patent Issue Date Used in PTA Calculation Critical | 02 Jul, 2013 | US8474447 |
| Recordation of Patent Grant Mailed Critical | 02 Jul, 2013 | US8474447 |
US patents provide insights into the exclusivity only within the United States, but Atrovent Hfa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Atrovent Hfa's family patents as well as insights into ongoing legal events on those patents.
Atrovent Hfa's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Atrovent Hfa's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 17, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Atrovent Hfa Generic API suppliers:
Ipratropium Bromide is the generic name for the brand Atrovent Hfa. 18 different companies have already filed for the generic of Atrovent Hfa, with Apotex Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Atrovent Hfa's generic
Alternative Brands for Atrovent Hfa
There are several other brand drugs using the same active ingredient (Ipratropium Bromide) as Atrovent Hfa. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Boehringer Ingelheim |
| ||
| Norvium Bioscience |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ipratropium Bromide, Atrovent Hfa's active ingredient. Check the complete list of approved generic manufacturers for Atrovent Hfa
About Atrovent Hfa
Atrovent Hfa is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. Atrovent Hfa uses Ipratropium Bromide as an active ingredient. Atrovent Hfa was launched by Boehringer Ingelheim in 2004.
Approval Date:
Atrovent Hfa was approved by FDA for market use on 27 November, 2004.
Active Ingredient:
Atrovent Hfa uses Ipratropium Bromide as the active ingredient. Check out other Drugs and Companies using Ipratropium Bromide ingredient
Dosage:
Atrovent Hfa is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.021MG/INH | AEROSOL, METERED | Prescription | INHALATION |